{"id":"xnw5004-placebo-chidamide","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"15-25%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-15%","effect":"Vomiting"},{"rate":"5-10%","effect":"Anemia"},{"rate":"5-10%","effect":"Thrombocytopenia"},{"rate":"5-10%","effect":"Neutropenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Histone deacetylases are enzymes that remove acetyl groups from histones, leading to chromatin compaction and reduced gene expression. By inhibiting these enzymes, chidamide promotes the expression of genes involved in cell cycle arrest and apoptosis, ultimately leading to the death of cancer cells.","oneSentence":"Chidamide is a histone deacetylase inhibitor that works by blocking the activity of histone deacetylases, leading to the accumulation of acetylated histones and the activation of tumor suppressor genes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:41:12.236Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory peripheral T-cell lymphoma"},{"name":"Relapsed or refractory cutaneous T-cell lymphoma"}]},"trialDetails":[{"nctId":"NCT06776952","phase":"PHASE3","title":"A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma","status":"RECRUITING","sponsor":"Evopoint Biosciences Inc.","startDate":"2025-04-10","conditions":"Relapsed/Refractory Peripheral T Cell Lymphoma","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"XNW5004 placebo; Chidamide","genericName":"XNW5004 placebo; Chidamide","companyName":"Evopoint Biosciences Inc.","companyId":"evopoint-biosciences-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Chidamide is a histone deacetylase inhibitor that works by blocking the activity of histone deacetylases, leading to the accumulation of acetylated histones and the activation of tumor suppressor genes. Used for Relapsed or refractory peripheral T-cell lymphoma, Relapsed or refractory cutaneous T-cell lymphoma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}